MedTrace Logo

Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer

NCT07691593 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-07-09

No results posted yet for this study

Summary

To evaluate the safety and efficacy of neoadjuvant HRS-4642 plus chemotherapy with or without adebrelimab in patients with pancreatic ductal adenocarcinoma.

Conditions

Interventions

DRUG

HRS-4642+NALIRIFOX

HRS-4642+NALIRIFOX

DRUG

HRS-4642+NALIRIFOX+Adebrelimab

HRS-4642+NALIRIFOX+Adebrelimab

DRUG

HRS-4642+NALIRIFOX+Adebrelimab

HRS-4642+NALIRIFOX+Adebrelimab

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-10-31
Completion
2028-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07691593 on ClinicalTrials.gov